MedTrace Logo

Efficacy and Safety of AN2898 and AN2728 Topical Ointments to Treat Mild-to-Moderate Atopic Dermatitis

NCT01301508 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 46

Last updated 2019-02-22

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether AN2898 and AN2728 ointments are safe and effective treatments for mild-to-moderate atopic dermatitis (AD).

Conditions

  • Dermatitis, Atopic

Interventions

DRUG

AN2728 ointment, 2%

AN2728 ointment, 2%, applied twice daily for 6 weeks

DRUG

AN2898 ointment, 1%

AN2898 ointment, 1%, applied twice daily for 6 weeks

DRUG

AN2898 ointment vehicle

AN2898 ointment vehicle applied twice daily for 6 weeks

DRUG

AN2728 ointment vehicle

AN2728 ointment vehicle applied twice daily for 6 weeks

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-05-31
Primary Completion
2011-11-11
Completion
2011-11-11

Countries

  • Australia

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01301508 on ClinicalTrials.gov